# Moderna Inc. Type: Company (MRNA) Source: GetYourBrief — https://getyourbrief.com/entity/moderna-inc Canonical HTML page: https://getyourbrief.com/entity/moderna-inc ## Timeline - **2026-07-20**: Cramer Endorsement & 109% YTD Gain — Motley Fool highlights 109% year-to-date surge and Jim Cramer's comment that Moderna is 'finally investable again'. - **2026-07-20**: Cramer Endorsement & 109% YTD Gain — Motley Fool highlights 109% year-to-date surge and Jim Cramer's comment that Moderna is 'finally investable again'. - **2026-06-26**: Chip Tumble and Moderna Rally — PHLX chip index dropped 5.3% on AI profitability concerns. Apple rebounded 3.1%. Moderna hosted an investor event, sending its stock up nearly 13%. S&P 500 closed marginally lower. - **2026-06-25**: Inflation Data Released and Apple Price Hike — May US inflation data showed a rise above 4%, fueled by energy costs from the Iran war. Apple raised prices on iPads and MacBooks, citing memory chip costs, leading to a sell-off in its shares. - **2026-06**: Quarterly Update — Moderna reports a 26% reduction in operating expenses, reiterates up to 10% revenue growth target for 2026. - **2026-06**: Quarterly Update — Moderna reports a 26% reduction in operating expenses, reiterates up to 10% revenue growth target for 2026. - **2026-03-15**: Public Criticism — Major editorials highlight the FDA's 'erratic' behavior as a threat to the broader innovation ecosystem. - **2026-03-15**: Market Impact — Moderna's valuation remains at roughly 10% of its pandemic-era high amid regulatory uncertainty. - **2026-03-15**: Industry Warning — Editorials warn that erratic FDA behavior is a threat to biotech innovation. - **2026-02-03**: Refusal to File — FDA's Vinay Prasad issues a formal refusal to review the flu vaccine application. - **2026-02-03**: Refusal to File — Senior regulator Vinay Prasad refuses to review Moderna's flu vaccine application, citing trial design concerns. - **2026-02-03**: Refusal to File — Senior regulator Vinay Prasad issues a rare letter refusing to review Moderna's flu vaccine application. - **2026-02-03**: Refusal to File — FDA regulator Vinay Prasad refuses to review Moderna's flu vaccine application. - **2026-02-03**: Application Refusal — FDA senior regulator Vinay Prasad issues a formal refusal to review the flu vaccine application. - **2025-12-31**: Grants Rescinded — The administration pulls back hundreds of millions in funding for mRNA-based research projects. ## Recent coverage (12 stories, network-wide) ### Moderna's 109% Stock Surge: What It Means for Global Health and mRNA Vaccines 2026-07-21 00:07:56 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2 Moderna’s financial rebound could accelerate the deployment of mRNA technology for RSV, flu, and future pandemics, enhancing public health resilience. Full story: https://gethealthbrief.com/story/moderna-health-mrna-impact-109 ### Moderna Up 109% YTD: Cramer Calls It Investable—Is It a Buy on the Dip? 2026-07-21 00:07:49 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 2 Jim Cramer’s bullish pivot comes as Moderna stock pulls back from its 109% YTD gain, raising the question: does the dip offer a compelling entry for investors? Full story: https://getfinancebrief.com/story/moderna-finance-cramer-dip-buying-109 ### After 109% Rally, Moderna’s Pipeline Progress and 10% Revenue Goal 2026-07-21 00:07:40 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2 Moderna’s cost cuts and pipeline milestones, from RSV commercialization to latent virus programs, are restoring biotech investor confidence despite past setbacks. Full story: https://getbiobrief.com/story/moderna-bio-pipeline-revival-109 ### Moderna Rockets 13% to 2024 Highs as Healthcare Outperforms 2026-06-28 00:00:21 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Moderna surged nearly 13% after an investor event, driving a broader healthcare rally as investors rotated out of tech. The S&P 500 healthcare sector benefited from defensive positioning amid AI chip turmoil. Full story: https://gethealthbrief.com/story/moderna-13-percent-healthcare-rally-june26 ### S&P 500 Ends Lower: Chips -5.3%, Moderna +13%, Inflation Above 4% 2026-06-28 00:00:13 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2 A volatile session saw the S&P 500 close marginally lower as a 5.3% chip sell-off collided with a 13% Moderna rally. With May inflation topping 4%, the Fed's next move remains a key market driver. Full story: https://getfinancebrief.com/story/sp500-chips-drop-moderna-surge-inflation ### Moderna Showcases Pipeline, Stock Surges 13%: Biotech's Big Day 2026-06-28 00:00:05 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Moderna's investor event sent its shares soaring nearly 13%, marking a pivotal day for the biotech industry. The rally highlights how pipeline disclosures can dramatically move markets and reaffirm investor appetite for innovation. Full story: https://getbiobrief.com/story/moderna-pipeline-event-13-percent ### AI Chip Stocks Tumble 5.3% as Profitability Questions Mount 2026-06-27 23:59:56 · Sector: ai · Sentiment: Neutral · Impact: 5/10 · Sources: 2 The PHLX semiconductor index dropped 5.3% as investors grow impatient with AI infrastructure spending. Doubts about near-term profitability and high capex are prompting a reassessment of AI-related chip valuations. Full story: https://getaibrief.com/story/ai-chip-stocks-plunge-5-3-percent ### Regulatory Volatility: FDA’s Moderna Rejection Signals New Risk for Biotech 2026-03-16 00:17:53 · Sector: startups · Sentiment: Negative · Impact: 8/10 · Sources: 2 Moderna faces a significant regulatory setback as the FDA refuses to review its new flu vaccine, citing trial design flaws despite previous guidance. This shift reflects a broader, politically charged environment that threatens to destabilize the venture-backed biotech ecosystem. Full story: https://getstartupbrief.com/story/fda-moderna-regulatory-volatility-biotech-innovation ### FDA Regulatory Shift Threatens Biotech Innovation and Moderna's Recovery 2026-03-16 00:17:19 · Sector: finance · Sentiment: Negative · Impact: 8/10 · Sources: 2 Moderna Inc. faces a critical juncture as the FDA's increasingly erratic regulatory stance and shifting White House sentiment jeopardize the future of mRNA technology. A rare refusal to review the company's flu vaccine data highlights a growing rift between the agency and the industry it oversees, threatening the predictability required for biotech investment. Full story: https://getfinancebrief.com/story/fda-regulatory-shift-moderna-innovation-threat ### FDA Regulatory Volatility and Political Shifts Threaten Moderna’s mRNA Pipeline 2026-03-16 00:16:43 · Sector: bio · Sentiment: Negative · Impact: 8/10 · Sources: 2 Moderna faces a critical setback after the FDA issued a rare refusal to review its flu vaccine application, signaling a shift in the regulatory and political climate for mRNA technology. This development, coupled with rescinded federal grants and a 90% decline in market value from pandemic peaks, highlights growing friction between the biotech industry and federal oversight. Full story: https://getbiobrief.com/story/fda-moderna-mrna-regulatory-threat ### FDA's Regulatory Shift Signals New Era of Uncertainty for mRNA Innovation 2026-03-16 00:16:10 · Sector: health · Sentiment: Negative · Impact: 8/10 · Sources: 2 The FDA's recent refusal to review Moderna's flu vaccine application marks a significant pivot in the regulatory environment for mRNA technology. This shift, characterized by increasing political pressure and unpredictable oversight, threatens to stifle the very innovation that defined the pandemic response. Full story: https://gethealthbrief.com/story/fda-moderna-mrna-regulatory-uncertainty ### FDA Regulatory Shifts and Moderna's Flu Vaccine Setback Threaten Innovation 2026-03-16 00:09:34 · Sector: legal · Sentiment: Negative · Impact: 8/10 · Sources: 2 The FDA's rare 'refusal to file' regarding Moderna's mRNA flu vaccine signals a pivot from pandemic-era collaboration to a more adversarial regulatory environment. This unpredictability, combined with rescinded federal grants and a 90% decline in market value, highlights the growing legal and compliance risks for biotech firms. Full story: https://getlegalbrief.com/story/fda-moderna-regulatory-risk-analysis --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.